about
Complications of vasectomyBenign prostatic hyperplasia and new treatment options - a critical appraisal of the UroLift systemIntegrative review on the non-invasive management of lower urinary tract symptoms in men following treatments for pelvic malignancies.Novel method for open-access laparoscopic port insertion using the killian nasal speculum: the lister technique.Clinical performance of the Prostate Health Index (PHI) for the prediction of prostate cancer in obese men: data from the PROMEtheuS project, a multicentre European prospective study.Developing a robotic prostatectomy service and a robotic fellowship programme - defining the learning curve.The early detection and diagnosis of bladder cancer: a critical review of the options.Sildenafil influences lower urinary tract symptoms.Diagnosis and medical treatment of lower urinary tract symptoms in adult men: applying specialist guidelines in clinical practice.Minimally invasive prostatic urethral lift: surgical technique and multinational experience.Safety and feasibility of the prostatic urethral lift: a novel, minimally invasive treatment for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH).Prevalence of undiagnosed diabetes mellitus in male erectile dysfunction.Prevalence of undiagnosed prostate cancer in men with erectile dysfunction.Preoperative Prostate-specific Antigen Isoform p2PSA and Its Derivatives, %p2PSA and Prostate Health Index, Predict Pathologic Outcomes in Patients Undergoing Radical Prostatectomy for Prostate Cancer: Results from a Multicentric European ProspectivThe Management of Unplanned Erection during Endoscopic Urological SurgeryDutasteride improves objective and subjective disease measures in men with benign prostatic hyperplasia and modest or severe prostate enlargement.Natural history of localised prostatic cancer.Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study.Multicenter European external validation of a prostate health index-based nomogram for predicting prostate cancer at extended biopsy.Can dutasteride delay or prevent the progression of prostate cancer in patients with biochemical failure after radical therapy? Rationale and design of the Avodart after Radical Therapy for Prostate Cancer Study.Can Anterior Prostatic Fat Harbor Prostate Cancer Metastasis? A Prospective Cohort Study.Clinical performance of serum isoform [-2]proPSA (p2PSA), and its derivatives %p2PSA and the Prostate Health Index, in men aged <60 years: results from a multicentric European study.The use of propofol sedation for transrectal ultrasonography-guided prostate biopsy is associated with high patient satisfaction and acceptability.Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEFirst 500 cases of robotic-assisted laparoscopic radical prostatectomy from a single uk centre: learning curves of two surgeons.Subpubic cartilaginous cyst: an unusual cause of urinary tract infection.Dutasteride Treatment Over 2 Years Delays Prostate-specific Antigen Progression in Patients with Biochemical Failure After Radical Therapy for Prostate Cancer: Results from the Randomised, Placebo-controlled Avodart After Radical Therapy for ProstateThe effects of extracorporeal shock wave lithotripsy on urological prostheses and endoprosthesesThe first randomized controlled trialIncreased patient satisfaction from transrectal ultrasonography and biopsy under sedationShould urologists do their own diagnostic ultrasonography?Phimosis after penile Mondor's phlebitisA study comparing various noninvasive methods of detecting bladder cancer in urineOptimizing erectile function after radical prostatectomySuccessful use of steroids and ureteric stents in 24 patients with idiopathic retroperitoneal fibrosis: a retrospective studyRe: Giorgio Guazzoni, Massimo Lazzeri, Luciano Nava, et al. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and Prostate Health Index, predict pathologic outcomes in patients undergoing radical prostatectomy for prosBenign prostatic hyperplasia: counting the cost of its managementCurrent prospects for the chemoprevention of prostate cancerEjaculatory dysfunction after treatment for lower urinary tract symptoms: retrograde ejaculation or retrograde thinking?Going with the flow! Relieving lower urinary tract symptoms and preserving ejaculation
P50
Q24670999-D0ED487E-7B7A-4DC9-A8E9-76990BF7AAFAQ26747709-2CA13EF3-C7DC-456C-8643-C6E4ECA08A96Q30373008-EA87385D-2C5D-4CDB-A53F-E18D8C948958Q30483721-B1CE0A61-FC8E-455F-A434-35DE1B36434CQ30843223-77729F17-A22E-42DA-B428-1357D9199A22Q33625723-4414F682-5792-4757-AC49-B664C87109F1Q34313938-F21A1233-8DC7-4E78-88B1-EF7B7E039980Q35013389-8591281D-5D22-467C-B3DB-8B980E1723FAQ37965267-8B541F0D-CF64-4CB9-A9E6-EF4EA95905B0Q39233563-F87F3FEC-0E55-45AB-8389-7E6B77DA75D2Q39266416-B268EFA7-6973-4B96-A449-18A06F7E4DAFQ39573205-03FB5524-3680-4F27-B503-E2E81F4CCF56Q39594629-A81DF76E-42BA-40FB-B488-3A52D50EDB39Q40216307-4CA7F1A5-1FB1-4E28-99B3-AB9B2CB6D4CCQ41601095-2EC0132D-287D-46A1-BB47-7FFF910B91DAQ42594595-7CE8C850-0ADF-48E7-867E-DB12D92E03B0Q43593549-96EFAAEF-3053-4A85-9E94-DE65BCDB79A1Q44486960-E627761F-93F1-4E40-A41F-FEB4568E7CF2Q45033695-A138CA1D-382B-4DDD-900C-79ACBE748180Q46117616-553625DB-A8B1-4DEA-BDE7-823F388B4CD1Q47138267-29718966-9F2A-4B8B-9F5E-1BEBC1DEC5A5Q48328454-AACD224C-8244-40A5-851F-046A8A23F7A8Q48623968-4A4A0A47-CF27-45D4-A57A-E6916B30BD5AQ50858265-C2D216DD-1213-4DC7-9844-D215CA4D08E8Q51857027-436F28AD-3AA4-4A9E-A5AE-152208811B67Q55265266-99967816-25AC-4219-A243-1ACEDE621535Q63966465-0CFED611-0A84-48DB-95A0-4715234A2C8CQ69738508-BD638D1F-2920-44CD-BEEA-4FE434D9A808Q73653856-E0FD926D-6D5C-45FF-9BB0-FDA086967766Q74040771-F20806B3-3619-4EBF-83CF-66B51DA30342Q75422254-93ACFECB-0042-41BF-AED6-7F10D0D75FE0Q77347534-0EB70292-3356-48DC-8CD4-651A95C7B7E2Q77711384-50460EBF-D695-48A5-8B61-ED6E05176837Q79805532-81C33E2A-D5F5-4D73-9B83-AC96ED9B673EQ80849440-EC650DD5-367D-4A41-96AF-9474866B0905Q84004025-B6A5FFDA-9E4B-4767-AE27-AF8D019025E3Q84588652-967798DC-1703-4748-8754-A5013B49E075Q84959567-D0931710-84B0-4DC0-87D4-087CF3C28877Q87420516-9B950E58-473C-4964-81AC-D0CFE53DBE30Q87442290-37E39BF7-E8AF-4494-A926-2F6010C79E9F
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Thomas McNicholas
@ast
Thomas McNicholas
@en
Thomas McNicholas
@es
Thomas McNicholas
@nl
type
label
Thomas McNicholas
@ast
Thomas McNicholas
@en
Thomas McNicholas
@es
Thomas McNicholas
@nl
prefLabel
Thomas McNicholas
@ast
Thomas McNicholas
@en
Thomas McNicholas
@es
Thomas McNicholas
@nl
P106
P1153
7003769249
P31
P496
0000-0001-9971-8765